Added to YB: 2026-09-04
Pitch date: 2026-09-02
CPH.TO [neutral]
Cipher Pharmaceuticals Inc.
-1.1%
current return
Author Info
Stocks & Stones manages the Rivemont MicroCap Fund, which has several million $ in assets. I’m here to help you avoid the pitfalls of microcap investing. Sign up for the newsletter.
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 259.4M
Pitch Price
CAD 14.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
9.37
P/E
9.09
EV/Sales
5.05
Sector
Pharmaceuticals
Category
N/A
The Good, the Bad, and the Ugly (August 2026) - Cipher Pharmaceuticals Inc.
CPH.TO (earnings): Cipher Pharmaceuticals reported an underwhelming second quarter, with reduced Medicaid coverage for Natroba, its main U.S. product, apparently not well telegraphed amid near-term uncertainty. Quarterly revenue and EBITDA each fell 10%, while EPS declined 30% year over year. The shares dropped as much as 25% over the following two days.
Read full article (1 min)